Form 4: Silence Therapeutics Director Richard Ian Griffiths Reports Acquisition of Shares

Director Richard Ian Griffiths reports purchasing Silence Therapeutics plc shares in two transactions on April 17 and April 21, 2025.

Summary

• Richard Ian Griffiths, a director of Silence Therapeutics plc, filed a Form 4 detailing changes in beneficial ownership.
• On April 17, 2025, Griffiths purchased 50,000 American Depositary Shares (ADS) at $3.14 each.
• Each ADS is immediately convertible into three ordinary shares.
• Following this transaction, Griffiths directly owned 10,111,299 ADS.
• On April 21, 2025, Griffiths purchased 100,000 American Depositary Shares (ADS) at $3.12 each.
• Following this transaction, Griffiths directly owned 10,211,299 ADS.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of share purchases by a director. The purchases themselves could be interpreted as slightly positive, indicating confidence, but the filing itself is simply a procedural requirement.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders.

Stakeholder Impact

• The share purchases by a director could potentially increase investor confidence.

Key Dates

Keywords

Silence Therapeutics, Richard Ian Griffiths, Form 4, Beneficial Ownership, ADS, Shares, Director, Transaction